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Abstract: The enormous versatility of mesoporous silica nanoparticles permits the creation of a
large number of nanotherapeutic systems for the treatment of cancer and many other pathologies.
In addition to the controlled release of small drugs, these materials allow a broad number of molecules
of a very different nature and sizes. In this review, we focus on biogenic species with therapeutic
abilities (proteins, peptides, nucleic acids, and glycans), as well as how nanotechnology, in particular
silica-based materials, can help in establishing new and more efficient routes for their administration.
Indeed, since the applicability of those combinations of mesoporous silica with bio(macro)molecules
goes beyond cancer treatment, we address a classification based on the type of therapeutic action.
Likewise, as illustrative content, we highlight the most typical issues and problems found in the
preparation of those hybrid nanotherapeutic materials.
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1. Introduction
Since the very first example reported on nanometric mesoporous silica as a drug delivery
material [1], many examples were subsequently reported including a broad number of chemical
species. One of them includes biomacromolecules, which play a capital role in living beings, as they
are responsible for biorecognition [2], signal transduction [3], and replication routes; hence, they are
responsible for the adequate development of tissues and organs. Such is the importance of these species
that even the immune system and hormone signaling are based on specific affinity interactions between
biomacromolecules (BMs). From a therapeutic point of view, hijacking such ligands and receptors may
be useful to regulate unbalanced systems, as well as develop new-generation therapeutic nanodevices
in oncology [4,5] cancer immunotherapy [6–8], and gene therapy [9–11], among many others.
Unfortunately, most bioactive macromolecules are highly labile in vivo, as a self-regulation
mechanism to avoid massive damages. Therefore, to use them, it is necessary to implement
chemical modifications or to design vehicles capable of ensuring an adequate preservation and,
hence, a long-lasting effect. Among known carriers, viruses have the best performance, although at
the expense of having a great associated risk in handling and containment. Additionally, they are
only suitable for nucleic acids (NAs), being useless for protein and peptide delivery. To overcome
these limitations, nanoparticles emerged as promising vectors for nucleotides, as well as peptides
and proteins. This is a consequence of two complementary aspects. On one hand, their size permits
establishing intimate interactions with cell’s membranes and the receptors therein. On the other
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hand, they exhibit the possibility to establish non-conventional interactions between particles, cargoes,
and target cells.
Amongst all known materials, mesoporous silica nanoparticles (MSNs) arose as promising
drug delivery platforms because of their outstanding biocompatibility, their degradability, and their
great chemical and biological robustness. Moreover, the unique porous structure of MSNs permits
establishing host–guest interactions of high interest for drug delivery purposes, as they allow
creating protective environments for labile molecules. In addition to those, the current silica-based
nanotechnology also permits creating particles with variable diameters [12,13], pore sizes [14],
and structures [15], which permit fine-tuning the final application of the nanosystems, especially
those intended to deliver big cargoes such as those reviewed herein. Moreover, MSNs and related
hybrid particles with SiO2 coatings also permit easily tuning the resulting outer layers of nanosystems
to enhance biochemical stability and, hence, to reduce side effects and potential toxicities [16–18].
Particle diameter is one of the most critical parameters for achieving a successful therapy. Typically,
the accepted window of diameters for cancer treatment comprises particles in a range between 50 and
300 nm, in which the enhanced permeation and retention effect operates. However, depending on
the final purpose of the nanosystem, such values may be narrowed. For instance, in cases where a
superior trafficking is desired, smaller particles would behave better, while, in nanosystems intended
as biomolecule reservoirs, the diameter must unavoidably be increased. Regarding nanoparticle-based
drug delivery, we recently reviewed how mesoporous silica-based nanosystems are suitable platforms
to combine two or more chemical species, outranging the pharmacological profile of free species [19,20].
However, despite the possible therapeutic improvement, their efficiency and long-term stability could
be compromised if the BMs are not properly protected or fully exposed to white blood cells and
immune systems. The scarce protection provided by most solid nanoparticles highlights once again the
importance of MSNs [21] as platforms for the development of non-viral vectors and protein carriers,
whose particular porous morphology can provide a protective environment for those labile molecules,
although the typical porosity (2–3 nm) of MSNs may be tuned in order to host the biggest molecules [22]
(Figure 1).Pharmaceutics 2020, 12, 3 of 43 
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As introduced, the use of MSNs in biomedicine has a huge potential impact; in addition to acting
as carriers, they also permit creating fancy structures with most functional nanomaterials. However,
despite this versatility, the permeation of these materials into clinical trials is still limited [23,24];
this is not caused by poor biocompatibility, but rather by the impossibility of establishing reliable
comparisons between different systems, as accounted by Florence [25]. In fact, as can be observed from
the growing number of in vivo experiments using MSNs carried out by many groups worldwide, it is
logical to assume that they have adequate performance in living systems; thus, MSNs will hopefully
soon reach clinical practice.
2. Strategies to Deliver Biomacromolecules with Silica Nanoparticles
Loading effectiveness, cellular internalization, targeting, and cargo delivery are critical issues
when developing a nanosystem with maximal therapeutic potential. As we previously mentioned,
MSNs are ideal nanocarriers related to the load and delivery of biomolecules due to their unique
properties, including shape, size, and surface chemistry [26]. Pore, channel, and cavity sizes can
be modified in MSNs to increase the loading of therapeutic molecules [27]. The MSN surface can
be functionalized with polyethyleneimine and poly-l-lysine or modified with targeting peptides or
antibodies to improve cargo loading, cellular uptake, and endosomal scape rates [26]. The chemical
and physical properties of MSNs are critical when designing a nanocarrier with therapeutic efficacy in
biomolecule loading and delivery. In the last few years, surface nanoscale topography gained special
attention due to the possibility of controlling the interactions between molecules and cells, in the
process of molecular loading and cell internalization [28,29].
The chemical functionalization of silica is easily achieved through condensation processes
employing functionalized alkoxysilanes. For the functionalization of surfaces, this silanization must be
carried out before template removal, while the modification of mesopores could be achieved either
via condensation during the template-driven synthesis of MSNs or after surface modification and
template removal. In this latter case, it is important to account that pore constriction may occur if the
process is not properly controlled. For the preparation of hollow MSNs (HMSNs), the most employed
method is the solid template etching of an internal core, typically from solid silica, onto which a
mesoporous layer is created. Pore and surface modification can be achieved in a parallel manner as
done with conventional MSNs, while, for the functionalization of the internal space, this must be
done prior to the formation of the mesoporous layer. Onto this slightly modified MSN, it would be
possible to create additional modifications by linking chemical species through conventional chemical
reactions. With this strategy, it was possible to create a huge number of functional nanosystems with
pore nanogates [30], sensitive bonds [31], recognition elements [5,19], and charged surfaces able to
undergo electrostatic interactions.
One common strategy to combine BMs and NPs is surface functionalization; it can be achieved
either via a chemical bond or via an electrostatic interaction between charged counterparts. On MSNs,
surface grafting is usually accomplished via direct condensation of the remaining Si–OH groups with
functional silane reagents; these are typically modified trialkoxysilanes with aliphatic chains bearing
an additional functional group. For the bonding of peptides and proteins, the most common functional
groups are amino and carboxylate for amide coupling and maleimides for thiol-mediated binding [32].
Additionally, to complement the direct coupling approach, there are also many different bifunctional
linkers available which are able to accomplish this task [33]. With regard to this coupling strategy,
it is also important to remark the importance of controlling the bonding, which, if produced at the
active region of proteins, may lead to inactivation. This is of particular importance when preparing
antibody-targeted nanosystems [34,35] and sensors. On this topic, Landry and coworkers studied
how the chemical linkage affected the specificity of cluster of differentiation 4 (CD4)-bonded proteins
onto MSN against its target, the gp120 glycoprotein [36]. The authors proved that a conventional,
unspecific, direct thiol–maleimide linkage behaved worse than a specific linkage placed far away from
the active site.
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The other approach for surface functionalization is electrostatic deposition. In this case, both
nanocarriers and BMs need to establish strong electrostatic interactions through differently charged
functional groups. This is of particular importance for NAs, whose permanent negative charge permits
strong interactions with positively charged surfaces and polymers such as polyethyleneimine or
chitosan among many others. Insights into this strategy are available in References [20,37]. In the
most advanced models, a rational deposition of alternating cationic and anionic layers—for instance,
polyethyleneimine (PEI)–small interfering RNA (siRNA)–PEI–, also permitted developing multilayered
nanosystems in which targeting elements could be added in the outermost layer. This design permits
placing NAs in middle layers, obtaining additional protection against nucleases. Moreover, this
strategy also enables pH-driven cleavage, which permits disassembling the system in endosomal
environments, as a consequence of the proton sponge effect associated with polycationic substances [38].
The main drawback of the surface loading strategy is the absence of protection for BMs, which could
be deactivated if exposed to blood (opsonization, enzymatic degradation, macrophage-mediated
clearance, etc.) [39] or if not properly handled during processing (non-sterile material, accidental
contamination, or physicochemical decomposition).
From a protective point of view, the use of pore-expanded MSNs [40] is the most convenient
strategy, but only if the cargo is adequately retained until its final destination. To this end, pore sizes
should be tuned to allow cargo hosting and, eventually, pore gates may be required [30]. The typical
strategies to prepare enlarged-pore MSNs consist of either using large surfactants such as Pluronic
or Brij [14] or employing swelling agents able to increase the diameter of the template cetrimonium
micelles during the synthesis [41]. Additionally, the use of non-surfactant species, like tannic acid,
was also reported as a pore-forming agent [42]. Regarding NAs, it is also important to remark that
raw pores of MSNs need to be chemically modified; otherwise, the negative charges of NAs and
silanols would undergo a repulsive interaction that would hinder pore loading. This topic was
previously visited by us and other groups in previous contributions [20,37]. In the case of proteins and
peptides, this effect is not so relevant, as their isoelectric points are always closer to neutrality. In fact,
most peptides behave as small molecules and can be loaded satisfactorily in most raw-pore MSNs.
In summary, the loading strategy must be carefully accounted for depending on the carried
biomacromolecule. In this way, short peptides can be easily loaded within pores or grafted onto
surfaces, while the delivery of bigger and highly charged molecules may suffer from pore rejection if
the mesopores are not properly conditioned [43]. Regarding NAs, their outstanding chemical stability
permits creating either fancy layered structures or pore-loaded systems [44–46]. In addition to typical
porous particles, the use of hollow mesoporous silica nanoparticles (HMSNs) also receives interest
because of their additional enormous internal space. However, to use them as carriers, their mesopores
and surfaces must comply with all requirements outlined for in-pore loading, i.e., sufficient diameter,
favorable electrostatic environment, and adequate order to permit effective diffusion processes.
In addition to cargo-related modifications, these kinds of nanodevices must also have additional
modifications to increase colloidal stability and immune stealth to ensure an adequate trafficking
profile (Figure 2). In the case of pore-loaded nanosystems, this can be easily achieved with a common
polyethylene glycol (PEG)ylation strategy. On coated nanosystems, it may not be necessary if the
particles’ coatings are naturally occurring biomolecules, such as those reviewed herein. In this case,
although the integrity of supported molecules is not fully ensured, surface deposition is proven to be a
synthetic advantage, as it greatly reduces the number of components and synthetic steps.
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3. Delivery of Proteins with Therapeutic Effect
As introduced above, the effect and potency of therapeutic proteins rely on their physiological
effect and behavior. For example, cytochrome c (Cyt c) triggers a caspase-mediated apoptosis, while
immunoglobulins activate the immune system and induce cell destruction. Additionally, certain
enzymes and growth factors may be useful to treat certain genetic diseases based on protein malfunction.
Therefore, as there is no common therapeutic effect [47], the different approaches are discussed including
pro-apoptotic, immunostimulating, enzymes, growth factors, and antibacterial proteins, according
to the classification shown in Table 1 and Figure 3. For the interested reader, previously published
outstanding revisions dealt with insights into protein loading and delivery with MSNs [48–51].
Table 1. Examples of therapeutic proteins delivered by silica-based nanocarriers.
Protein Carrier Type Protein Location Loading Strategy Cell Line(s) In Vivo Reference
Anticancer proteins [52,53]
Cytochrome C
MSNs Mesopores Pore filling HeLa None [54,55]
MSNs Surface Adsorption None None [56]
MSNs Surface Grafting HeLa None [57]
MSNs Mesopores Pore filling SKOV3 None [58]
Concanavalin A MSNs Surface Grafting MC3T3-E1, HOS None [59]
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Table 1. Cont.
Protein Carrier Type Protein Location Loading Strategy Cell Line(s) In Vivo Reference
Immunostimulating proteins and vaccines
IgG HMSNs Particle cavity Cavity loading HeLa None [60]
OVA HMSNs Mesopores Pore filling NIH3T3 Mice [61,62]
OVA DMOHS Mesopores Pore filling None Mice [63]
CpG@OVA MSNs Mesopores Pore filling RAW264.7 Mice [64]
CpG@OVA
GM-CSF
MSNs@
MSRs
Mesopores
Mesopores Pore filling None Mice [65]
Cyt c, IgG,
Anti-pAkt RSNs Interparticles In-pocket packing None None [66]
IL-2 HMSNs Particle cavity Cavity loading L929 Mice [67]
ORF2 HMSNs Surface Adsorption PK15 Mice [68]
SWAP MSNs Surface Adsorption None Mice [69]
HSP700 MSNs Surface Adsorption None Mice [70]
EspA MSNs Surface Adsorption None Mice [71]
rPb27 MSNs Surface Adsorption HEK-293 Mice [72]
Enzymes
CA MSNs Mesopores In-pore grafting HeLa None [73]
CA or HPR MSNs Mesopores In-pore grafting None None [74]
β-Galactosidase MSNs Mesopores Adsorption N2a None [75]
SOD MSNs Surface Grafting HeLa None [76]
SOD or GPx MSNs Surface Grafting HeLa None [77]
Proteasomes MSNs Surface Grafting HEK-293, HeLa None [78]
Growth factors
bFGF MSNs Mesopores Microemulsion HUVEC None [79]
BMP-2
MSNs Surface Adsorption bMSCs Mice [80]
MSN@SPION Mesopores Pore filling bMSCs None [81]
Antibacterial proteins
Lysozyme
MSNs Surface Grafting Escherichia coli Mice [82]
MSNs Pores Adsorption E. coli None [83]
HMSNs Surface Adsorption E. coli Mice [84]
HMSNs Particle cavity Cavity loading E. coli None [85]
Concanavalin A MSNs Surface Grafting E. coli None [86]
Abbreviations: bFGF: basic fibroblast growth factor; BMP-2: bone morphogenetic protein 2; bMSCs: murine bone
mesenchymal stem cells; CA: carbonic anhydrase; CpG@OVA: ovalbumin-loaded cytosine–phosphate–guanine
(CpG) oligodeoxynucleotide; DMOHS: dendritic mesoporous organosilica hollow spheres; EspA: an immunogenic
protein from enterohaemorrhagic Escherichia Coli; GM-CSF: murine granulocyte-macrophage colony-stimulating
factor; GPx: glutathione peroxidase; HMSNs: hollow mesoporous silica nanoparticles; HRP: horseradish peroxidase;
IgG: immunoglobulin G; IL-2: interleukin-2; ORF2: open reading frame from porcine circovirus type 2; OVA:
chicken ovalbumin; RSNs: rough (non-porous and core–shell) silica nanoparticles; SOD: superoxide dismutase;
SPIONs: superparamagnetic iron oxide nanoparticles.
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3.1. Anticancer Proteins
Historically, Lin’s group was the first to describe the potential of MSNs to carry and deliver proteins.
To achieve this, they focused on Cyt c, a small protein with a pro-apoptotic effect. In their contribution,
they pioneered pore-expanded MSNs to allow protein hosting, highlighting the strategy to follow for
the intracellular delivery of membrane-impermeable proteins [54]. Herein, they demonstrated that
unmodified MSNs with 5.4-nm mesopores were able to host the globular 3.3-nm-width protein to
produce effective intracellular delivery, although with no control. To improve this, Griebenow and
coworkers evolved a system including a chemical bond able to retain Cyt c inside the esopores.
Their stimulus-responsive system was based on a redox-sensitive disulfide bond that linked Cyt
c to thiol-modified mesopores [55], enabling an intracellular, glutathione-mediated release. Shang
et al. also employed Cyt c as a model protein for MSN-based delivery, although, in their system,
surface adsorption was preferred [56]. In this contribution, the authors did not evaluate the carrier
efficiency or the stability of the protein but studied the loading capacity—protein activity—in relation
to nanoparticle size. Their results showed that flatter surfaces—larger diameters—permit adsorbing
more proteins and, hence, provide higher activities. Another example employing Cyt c was reported by
Davis and coworkers, who studied the best-performing linker to connect the protein onto the particles’
surface [57]. In their research, they systematically tested several custom-made linkers against the most
critical parameters on optimal delivery for surface-grafted proteins: suitable charging capacity (>40 mV
on ξ-potential), cationic character at acidic pH, ability to undergo endosomal escape, and capacity to
permanently retain Cyt c immobilized on the surface. They found that MSNs modified with 1 mol.%
primary amine were the only material able to satisfactorily accomplish all these tasks, providing a
fantastic know-how for subsequent investigations into surface grafting. More recently, Choi et al.
explored another possibility to deliver Cyt c, employing eroded MSNs with rougher surfaces and
enlarged pores [58]. Herein, these matured MSNs permitted loading the Cyt c instead of obtaining the
surface deposition that occurred onto particles bearing conventional (2–3 nm) pores. As a result of the
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increased in-pore loading, the particles showed an enhanced release compared with both the free Cyt c
and the nanosystem with higher surface deposition.
Apart from Cyt c, there were reported numerous anticancer proteins [52,53], albeit few examples
in combination with MSNs. A relevant example on the topic was reported with concanavalin A,
a lectin with anticancer and antibacterial properties [59,86]. Regarding the anticancer example,
the lectin also proved to be an efficient targeting element against human osteosarcoma (HOS) and
murine prosteoblast (MC3T3-E1) cells. In our system, MSNs were firstly loaded with the typical
chemotherapeutic doxorubicin (DOX) and then coated with a polymeric layer linked to the silica surface
through pH-sensitive linkers. To conclude, the concanavalin A (ConA) was grafted onto the surface
through amide bonds. The resulting system was able to efficiently deliver the drug intracellularly,
but only when the pH dropped enough to cleave the bis-acetal linker. The evaluation of the system
demonstrated an enhanced killing effect when both species (ConA and DOX) were co-delivered.
This suggested a potent adjuvant effect of the protein, which was able to drop the cell viability from
50% with DOX alone to almost 100%.
3.2. Immunostimulating Proteins
Immunostimulation is one of the most popular strategies for improving cancer treatment, as it
promises to recruit the patient’s immune system to fight tumors. However, any indiscriminate activation
may lead to disastrous results. Therefore, there is interest in developing immunostimulant nanosystems
able to induce local immune responses thanks to the enhanced permeability and retention (EPR) effect.
MSN-based immunotherapy also has an additional advantage, as these particles were proven to be
efficient coadjutants [87–89]. Despite these promising features, the delivery of immune-regulating
proteins with silica-based carriers is still in its infancy.
Regarding already reported examples, proteins and MSNs can be combined via either surface
deposition—grafted or not—or loading into enlarged pores, although those are not the only options.
One such exception was the contribution by Lim et al. who delivered immunoglobulin (IgG) to
HeLa cells employing a very special silica particle [60]. These were called unconventional perforated
HMSNs. Those particles were able to efficiently deliver large membrane-impermeable cargoes,
although without any study on immune response. However, their contribution established the
basis for local immunostimulation, opening the way to new therapeutic strategies. In more recent
examples, several research groups studied immune inductions in mice using nanoparticles. Along
this line, Wang, Ito, Tsuji, and coworkers reported a series of articles which firstly studied the
immunostimulating behavior of HMSNs [87–89] in murine models, and then studied how the surface
modification of such HMSNs with the T cell-dependent antigen, chicken ovalbumin (OVA), stimulated
the overall response [61]. The authors paid special attention to which markers were upregulated
when treating the animals with these devices [62]. They found a four-action pathway: an anticancer
effect through the use of HMSNs themselves, an effector memory on the CD4+ and CD8+ T-cell
population, an overexpression on T helper 1 (Th1) and Th2 cytokines, and an enhanced secretion of
immunoglobulin antibodies [62]. Employing another silica nanostructure, a multi-shelled dendritic
mesoporous organosilica hollow sphere (DMOHS), Yang et al. also obtained similar stimulation
patterns when they employed OVA-loaded particles [63]. Herein, a parallel upregulation on CD4+,
CD8+, and Th1 immunoproteins was also reported, characterized by the secretion of interleukin-12
(IL-12), interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α). More recently, Cha et al. evolved
this system by adding an additional immunostimulating entity. In their model, large-pore MSNs
(20–30 nm) were sequentially loaded with OVA plus an additional “danger signal”, an agonist for
Toll-like receptor 9 (TLR9) [64]. As a result, an increased immunostimulation was obtained, which again
suggests the importance of combined therapies for the development of more effective cancer treatments
and vaccines. More recently, these authors implemented their immunostimulant nanosystem by
designing a combination of these MSNs embedded in large chemokine-loaded mesoporous nanorods
suitable for injection [65]. With this system, the authors overcame the limitations of the intravenous
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dosage of their previous nanosystem, as, with this approach, they could effectively recruit and mature
the dendritic cells in order to achieve a more efficient cancer vaccination. Their final formulation
demonstrated a significant tumor progression reduction together with great survival rates.
In addition to the typical strategies to link proteins onto nanoparticles, Niu et al. reported
another possible approach for protein delivery. They designed different porous systems with variable
cavities by controlling a core–shell assembly between solid silica nanoparticles. In their designs, core
particles had a preset size, while encircling particles had smaller but variable diameters. The resulting
disposition created different interparticle voids able to host different sized proteins [66]. The resulting
nanostructures showed variable roughness (14, 21, and 38 nm, respectively) that permitted satisfactorily
loading a wide variety of proteins, such as Cyt c, monoclonal rabbit antibodies (IgG), and even antibody
fragments (horseradish peroxidase (HRP)-linked anti-rabbit IgG antibody), preserving in all cases their
activities, as demonstrated by surface plasmon resonance. From a therapeutic point of view, the most
interesting model was the 38-nm hydrophobically modified rough (non-porous and core-shell) silica
nanoparticles (RSNs), which were able to deliver the anti-pAkt antibody into MCF-7 breast cancer
cells. In this case, the therapeutic effect occurred because the antibody created a significant reduction
of cell proliferation, together with a downregulated expression of the anti-apoptotic B-cell lymphoma 2
(Bcl-2) protein.
In addition to immunogenic proteins, another interesting therapeutic possibility enabled by
nanotechnology is non-viral-based vaccination [90,91]. Therefore, this could be achieved if antigens
are delivered to immune cells, thereby avoiding a general immune response. One of the first examples
of vaccination employing silica nanoparticles was reported by Guo et al., who employed HMSNs
to deliver the open reading frame of the porcine circovirus type 2 (ORF2) protein using a murine
model [68]. In this case, the nanovaccine was prepared via direct adsorption of the protein onto raw
nanoparticles. In mice, the MSN-based delivery of ORF2 induced overexpression of the typical markers:
IFN-γ, Th1, CD4, and CD8, suggesting an immune activation. This strategy was also successfully
employed to create other specific MSN-based non-viral vaccines for mice: (1) against Schistosoma
mansoni employing homogenates from the parasite [69]; (2) against porcine enzootic pneumonia by
using a recombinant heat-shock protein 70 (HSP70) antigen fragment (HSP70212–600) from Mycoplasma
hyopneumoniae [70]; (3) against enterohaemorrhagic Escherichia coli by using a recombinant fragment of
filamentous immunogenic protein from enterohaemorrhagic E. coli (EspA) protein [71]; (4) against
the pathogenic fungus Paracoccidioides brasiliensis employing the antigenic protein rPb27 [72]. In light
of these results, it is noteworthy to highlight that these nanoparticle-based vaccinations permit
immunizing against different types of pathogens, such as parasites, fungi, or bacteria, with a better
profile than the free antigen or other known pharmacological formulations in which the delivery
toward macrophages is not so efficient.
3.3. Enzymes
The deregulation of normal enzymatic levels has a fundamental role in many diseases. For example,
toxic or metabolic syndromes are a direct consequence of this protein malfunction. In cancer,
the deregulation of homeostasis is also a consequence of an abnormal expression of proteins and
enzymes. However, the use of enzymes in therapy clearly goes beyond cancer treatment based on the
delivery of cell-damaging proteins. Unfortunately, like all proteins, enzymes usually do not nicely
tolerate systemic administration unless properly modified [92]. Such is the case of the p53 anticancer
protein capsule designed by Zhao et al. [93] or the collagenase capsule reported by Villegas et al. [94],
which performed best only when they had a degradable protective shell. With regard to the enzymes
delivered by MSNs, it is important to remark that most examples are located at the surface; otherwise,
the diffusion of both substrates and products may be difficult. One of the most studied examples
is carbonic anhydrase (CA), which, despite not having a significant therapeutic effect, was widely
employed as a model for in-pore loading approaches [73,74]. The advantage of CA as a model is
a direct consequence of the facile determination of its remaining activity, as both substrate (CO2)
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and final product (HCO3−) are small enough to diffuse through the pores with freedom and can be
easily determined.
Regarding therapeutic models, the mitigation of toxic syndromes caused by genetic disorders is
one of the most promising research fields. One interesting example was reported by Xu et al. [75], who
employed MSNs to deliver β-galactosidase (β-Gal) to treat Morquio B syndrome. This disease appears
when the enzyme is not able to properly cleave the glycoside bond on oligosaccharides, thus producing
the accumulation of substrates. In this case, contrary to other models in which the enzyme was located
on the surface, the authors decided to load it into the mesopores to obtain additional protection and
long-term stability. In this case, the significant size (119 kDa) of β-Gal made it mandatory to prepare
ultra-large-pore MSNs. For this, the authors created core–cone structured MSNs with dahlia-like
mesopores that were able to host, preserve, and deliver catalytically active β-Gal to N2a cells. In this
case, the large size of mesopores, together with the small sizes of both enzymatic substrates and
products, permitted supporting the enzyme within the pores; however, in other cases, in which the
substrates have diffusion barriers because of the size or nature, this approach may not be so convenient.
With regard to supported proteins, Mou and coworkers reported the use of two antioxidant
enzymes, superoxide dismutase (SOD) and glutathione peroxidase (GPx), to intracellularly deplete
reactive oxygen species (ROS). In this case, the different nature of possible substrates demanded
an adequate exposure of proteins on the nanosystem; otherwise, they would not be able to
prevent oxidative stress. In their first example, the authors developed a mesoporous silica-based
multifunctional nanocarrier for SOD [76]. This device employed an Ni+2-chelated nitrilotriacetic acid
(Ni-NTA)-modified silane, which was able to connect through a histidine moiety to a TAT-containing
peptide sequence bound to the enzyme. At this point, the authors denatured the enzyme with urea in
order to have only intracellular refolding and to avoid extracellular ROS depletion. The resulting system
was able to internalize into HeLa cells and, therein, refold the enzyme into its active form and reduce
the oxidative stress induced by paraquat, a well-known superoxide anion generator. More recently,
the authors implemented the antioxidant performance of this model by employing two differently
loaded nanodevices: one with SOD and the other with GPx [77]. With this combination, the authors
found a complementary synergic effect in which the co-delivery of both antioxidant proteins improved
the effect of single treatments.
Another interesting example, reported by Han et al., focused on the delivery of human proteasomes
to delay tau aggregation associated with Alzheimer’s disease [78]. In this model, the authors employed
the same building strategy reported by Mou’s group: Ni-NTA able to bind histidine moieties from
active human 26S proteasomes isolated from a HEK293-derived cell line. Again, the system proved
to deliver proteasomes without a significant proteotoxic effect associated with its enzymatic activity.
At this point, the authors claimed that their system was not intended to permeate the blood-brain
barrier, although it could be implemented onto permeable systems, opening the way to novel strategies
to prevent and treat Alzheimer’s.
3.4. Growth Factors
Growth factors are biomacromolecules responsible for inducing cellular growth, proliferation, and
differentiation; they also play important roles in wound healing, bone formation, and vascularization.
The most known growth factor is somatotropin, the human growth factor, which is widely employed
to promote impaired growth in healthy individuals. The main drawback of this therapy is the need to
accomplish a continuous—intramuscular or subcutaneous—dosage in order to achieve a sustained
effect. Because of this, it is a treatment with very low adherence and, therefore, it needs improvement.
Among the new strategies developed, the most promising are those that permit reaching long-lasting
formulations with noninvasive administration routes [95,96]. With regard to the remaining growth
factors, mostly cytokines and steroid hormones, it is typical to have compounds with very little
aqueous solubility. As a result, they also require form delivery agents to perform their action properly.
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This need could be a niche for non-biogenic carriers, especially those of high loading capacity such as
silica-based platforms.
Regarding the examples available in the literature, ten years ago, Zhang et al. already reported the
potential of MSNs as carriers for growth factors [79]. In this contribution, a water-in-oil microemulsion
strategy was employed to create ad hoc MSNs for the 18-kDa basic fibroblast growth factor (bFGF)
protein. The resulting system was able to release the protein for over 20 days, and it could be
satisfactorily taken up by HUVEC cells. Moreover, the cytotoxicity assay showed low toxicity even
when administered at high concentrations (50 µg/mL). Despite this promising result, the remaining
examples with therapeutic growth factors are limited to two contributions by Gan et al., who employed
two complementary approaches for the delivery of the bone morphogenetic protein 2 (BMP-2).
In their first contribution, they prepared chitosan-coated MSNs to deposit proteins onto the particles’
surfaces [80], while, in their second work, SBA-15 microparticles with iron oxide nanocaps were
employed to load the protein within the 6.2-nm mesopores [81]. In the first example, the authors
included dexamethasone, a corticoid, into the mesopores to increment bone growth due to co-delivery
of two osteogenic species. Unfortunately, although a significant osteogenesis was achieved, it was
completely uncontrolled, and significant ectopic bone formation occurred. To prevent this, the authors
changed the model to deliver only the growth factor. To do so, they employed large-pore silica
microparticles to carry the BMP-2 and Fe3O4 nanocaps to prevent a premature release. The resulting
pH-driven carrier was able to deliver the protein while exhibiting excellent biocompatibility, but only
in vitro, where the huge size of the chosen silica particles did not affect the guest survival.
3.5. Antibacterial Proteins
In addition to the previous examples, it is also possible to transport proteins bearing antimicrobial
effects. On the delivery of antibacterial proteins with MSNs, most contributions were made
with lysozyme, a 14.4-kDa enzyme known to damage bacterial cells by hydrolyzing the major
component of Gram-positive bacterial walls, i.e., the β-1,4 bonds between N-acetylmuramic acid
and N-acetyl-d-glucosamine. The first example, reported by Lin et al., employed negatively charged
MCM-41 MSNs to bind lysozyme units through electrostatic interactions to provide a stable corona [82].
This model permitted having an antibacterial effect even on Gram-negative bacteria such as E. coli. Such
an effect was a consequence of the high concentration of lysozyme released in bacterial surroundings.
Although forthcoming models improved the antibacterial performance of this device, in this work, the
authors set two important advances: the possibility of treating bacterial infections with nanotechnology,
and the finding that even Gram-negative bacteria could be highly damaged by these glycoside
hydrolase enzymes.
In light of these previous results, Yu’s group attempted to improve the antibacterial capacity by
using higher-loading carriers. In one contribution, they differently evaluated dendritic pore MSNs,
finding that a bigger pore led to a faster release and, thus, higher antibacterial effects [83]. In the
second contribution, they developed silica nanopollens, which are engineered non-porous hollow
nanoparticles coated with nanosized silica spikes to provide a rough surface [84]. Similarly, to the
former model, they evaluated different roughnesses, finding that a rougher surface led to a better
loading and the associated antibacterial effect. A comparison between models seemed to indicate
that, in the case of large-pore MSNs, the antibacterial effect of lysozyme was a consequence of a
faster release, while, in the case of nanopollens, it was a combination of a more sustained release
together with an unknown nanoparticle-induced effect. Unfortunately, these models were only tested
on planktonic bacteria. To address a more complex situation in which the bacteria form a biofilm,
Ye and coworkers studied hollow MSNs as high-capacity nanocarriers (up to 350 mg per gram in
the case of their enlarged pore HMSNs) [85]. In this work, the authors reported a threshold for free
lysozyme activity (400 µg/mL), over which there was no therapeutic improvement. However, the use
of MSN-based delivery raised that maximal effect, as they showed a more sustained release pattern
able to induce a long-lasting effect.
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Apart from lysozyme, antibacterial effects with other proteins were also reported such as ConA
(in this case, in combination with levofloxacin) [86]. In this example, carboxylate-modified MCM-41
MSNs were functionalized with ConA upon drug loading. Herein, the combined action of both species
permitted achieving complete biofilm destruction even at minimal concentrations (10 µg MSNs per
mL), improving the precedent models due to combination therapy. In addition to these reported
models, there are many more proteins that lead to successful combinations [97]. Such is the case of
lactoferrin, known for having antibacterial properties [98], which was extensively employed in the
preparation of glioblastoma-targeted nanodevices [99,100].
4. Delivery of Peptides with Therapeutic Effect
Many of known bioactive peptides are simplified amino-acid sequences that replicate the active sites
of proteins and enzymes. The success of these peptides is a consequence of two complementary aspects:
(1) the ability to retain features from their parent proteins, and (2) an outstanding chemical profile
that arises from their facile synthesis, significantly low cost, and chemical robustness. Those aspects
permitted discovering a large number of peptides of different nature and specificity. For example,
regarding targeting, those sequences are selected for their affinity toward eukaryotic [101,102] or
prokaryotic [103,104] cell receptors. However, applications of peptides go beyond targeting [105],
as they are able to accomplish different tasks in regulating metabolic cycles and signaling. In this
section, we focus on the potential of MSN-carried peptides for the development of new therapeutic
devices. As shown in Table 2 and Figure 4, their applications range from cancer treatment [106–108] to
antibacterial effects [107,109], cell regulation processes [110], and immunostimulation.Pharmaceutics 2020, 12, 16 of 43 
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Table 2. Examples of different types of therapeutic peptides delivered by mesoporous silica-based nanocarriers.
Peptide Carrier Pore Cargo Release Mechanism Cell Line(s) In Vivo Reference
Anticancer Peptides
K8-Citraconate
K8(RGD)2
MSNs Doxorubicin Electrostatic COS7, U87 MG None [111]
TPP-K-(KLAKLAK)2- MSNs Topotecan
Electrostatic/Redox
cleavage KB None [112]
C-GRK2R2QR3P2Q-RGDS
C-GKGG-D(KLAKLAK)2
MSNs Doxorubicin Redox cleavage HeLa, COS7 None [113]
(RGDWWW)2KC MSNs Doxorubicin Redox cleavage COS7, U87 MG Mice [114]
(KLAKLAK)2 MSNs Doxorubicin
Enzymatic degradation
Redox cleavage HeLa None [115]
ε-poly-l-lysine
C9h MSNs C9h
Enzymatic degradation
Pore release HeLa None [116]
RDG-Hylin a1 MSNs RDG-Hylin a1 Pore release HeLa Hep2 Mice [117]
Pepstatin A HMSNs Pepstatin A Release from cavity MCF-7 None [118]
NuBCP9 MSNs NuBCP9 Pore release HeLa, HEK293 Zebrafish [119]
NuBCP9 PAMAM@MSNs NuBCP9 Pore release uponPAMAM detachment
HepG2,H292,
MCF-7,HeLa Mice [120]
Immunostimulating Peptides
HGP100
TRP2 HMSNs
HGP100
TRP2
Lipid layer disassembly
Release from cavity BMDCs None [121]
Antibacterial Peptides
LL37 SiO2/MSNs None/LL37
Surface adsorption vs.
pore release E. coli None [122]
NZX MSNs NZX Pore release Mycobacteriumtuberculosis Mice [123]
Melittin MSNs@MagMSNs
Melittin
Ofloxacin
Pore release upon
hyperthermia triggering
Pseudomonas
aeruginosa Mice [124]
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Table 2. Cont.
Peptide Carrier Pore Cargo Release Mechanism Cell Line(s) In Vivo Reference
Hormones and Growth Factors
Insulin
MSNs cAMP Glucose-mediateddisplacement RIN-5F None [125]
MSNs Insulin Glucose-sensitivepolymer shell None None [126]
MSNs Insulin Pore release Caco-2 None [127]
Osteostatin MSNs Osteostatin Pore release MC3T3-E1 Rabbit [128–130]
OGP MSNsMS-HANs OGP Pore release None None [131]
BMP-2 MSNs Surface None BMSCs Rat [132]
For an illustrative revision of the coupling protocols employed for linking peptides onto nanocarriers, please check Reference [133]. Abbreviations: BMDCs: murine bone-marrow-derived
dendritic cells; BMP-2: bone morphogenetic protein 2; BMSCs: rat bone mesenchymal stem cells; cAMP: cyclic adenosine monophosphate; MagMSNs: SPION@MSNs core–shell
nanoparticles; MS-HANs: mesoporous silica–hydroxyapatite nanoparticles; OGP: osteogenic growth peptide; PAMAM: polyamidoamine dendrimer.
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4.1. Anticancer Peptides
Typically, anticancer effects of peptides occur through two possible mechanisms. One of these arises
when the peptide is able to disrupt the normal function of the membrane, while the other occurs when it
triggers pro-apoptotic pathways. The membrane-disrupting mechanism operates when the peptides are
enriched with cationic amino acids: lysine (Lys, K; amine), arginine (Arg, R; guanidine), and histidine
(Hys, H; imidazole). Although this mechanism is not fully clear, these peptides demonstrated a
certain membrane-lytic effect similar to other cationic species [134]. The first evidence on the topic
was observed with TAT-targeted nanosystems [135], as well with other cell-membrane-penetrating
peptides [136].
Regarding the use of cationic peptides as therapeutic agents, it is highly desirable to hide their
cationic character to prevent premature damages such as hemolysis and embolisms during trafficking.
Apart from pore loading, which preserves cargoes from undesired interactions, another interesting
possibility arises from the use of additional negative components to balance the resulting surface
charge. One elegant strategy, reported by Zhang and coworkers, employed citraconic anhydride to
transform an octa-lysine into a negatively charged peptide able to balance the cationic K8(RGD)2
functionalized MSNs [111]. The resulting outermost layer was able to accomplish three tasks: target
integrin receptors through the RDG moiety, show a highly biocompatible neutral charge, and carry a
detachable but toxic K8 sequence. Unfortunately, the reported studies mainly focused on assessing
the effect of carried DOX than on studying the effect of the peptide release, overlooking any potential
anticancer effect. In a later contribution by these authors, their system was evolved by including
a triphenyl phosphonium group into the KLA peptide sequence (KLAKLAKKLAKLAK) in order
to target the mitochondrion. Mitochondria appeared as a key target in cancer treatment because of
their roles in regulating cell apoptosis and metabolism [137]. The delivery of antitumoral therapeutic
molecules to mitochondria may improve their therapeutic efficacy while avoiding resistance pathways.
Furthermore, stimulation of apoptosis mediated by mitochondria could also improve the efficacy of
cancer therapy. The resulting organelle-targeted compound was bound to MSNs through disulfide
bonds, known to be broken intracellularly by glutathione. Finally, to prevent undesired damages,
the authors created a PEGylated anionic polymer shell aimed at increasing biocompatibility and
reducing the leakage of topotecan [112]. In this system, the non-loaded model was able to exert a
significant pro-apoptotic even at low concentrations, proving the potential of peptides in anticancer
therapies; however, as expected, the highest antiproliferative effect occurred when topotecan was
loaded within the mesopores.
Encouraged by these results, this group also addressed the synthesis of a multiple pro-apoptotic
nanosystem: delivery of DOX, in combination with the delivery of two therapeutic peptides with
glutathione-mediated cleavage [113]. In this model, the employed peptides contained different
membrane-disrupting sequences, together with two different targeting elements: one of them
specific to mitochondrion (C-GKGG-DKLAKLAKKLAKLAK) and the other specific to membranes
(C-GRKKRRQRRRPPQ-RGDS). Additionally, to increase the potential cellular damage, the mesopores
were loaded with DOX while the peptides were bonded to particles through disulfide bonds, in order
to induce oxidative stress upon glutathione depletion. As result, the complete system showed high
efficiency against HeLa and COS7 cells, although this effect decreased significantly in the absence of
the drug, which highlights the limited effect of membrane-lytic peptides. More recently, this group also
employed the glutathione-mediated disulfide cleavage to prepare a drug delivery system for DOX and
a membrane-targeted therapeutic peptide rich in tryptophan ((RGDWWW)2KC) [114]. In this case,
this peptide was designed to have a DNA-intercalant effect due to the high concentration of indoles.
This postulate seems to be justified based on the toxicity obtained for such a nanosystem; however,
as expected, the best effect was obtained when DOX was co-delivered. More recently, Feng’s group
also employed this coating approach to co-deliver DOX and the anticancer peptide KLA. In this
model, the final capping was done with a bovine serum albumin (BSA) corona [115], which permitted
achieving a double effect: creating a diffusion barrier for both therapeutic agents, and enabling a
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protease/glutathione-mediated intracellular release. An interesting aspect of the system is that BSA
was employed in its wild-type form, which might trigger an additional cellular response when in
combination with the remaining multi-apoptotic effects.
Regarding the delivery of peptides that trigger pro-apoptotic routes, the reported examples
focused on threading such peptides into the mesopores. For example, Martínez-Máñez’s group
reported the use of ε-polylysine as a coating layer to prevent the leakage of the pro-apoptotic C9h
(YVETLDDIFEQWAHSEDLK) peptide [116]. In this model, the polylysine coating had multiple roles,
as it favored cellular uptake due to its cationic character, while maintaining the C9h peptide within the
mesopores until proteases cleaved this protective layer. The in vitro testing of this model proved that
the encapsulated peptide showed a better therapeutic profile that its free form. However, this effect
reached a maximum plateau over which higher dosages did not augment apoptosis. This points out
once again the limited anticancer effect of peptides, which demand additional chemotherapeutic agents
to obtain satisfactory results. In another similar example employing pore modifications, Cao et al.
reported the delivery of a different proapoptotic peptide. In this model, they employed large-pore
MSNs to deliver a bifunctional RGD-containing Hylin a1 peptide (IFGAILPLALGALKNLIK) able
to target and kill cancerous cells [117]. To accommodate the peptide, the authors functionalized the
internal facets of mesopores to favor threading and enable a pH-dependent release. In vitro studies
of this system showed that encapsulation drastically reduced the hemolytic rate shown by the free
peptide without affecting the potent cytotoxic effect against HeLa and Hep2 cells in vitro. Published
in vivo studies with this system showed a clear tumor growth arrest in murine models, although,
unfortunately, complete tumor remission could not be achieved.
As previously outlined, the anticancer effect of peptides and proteins is relatively low; thus, their
use is generally limited to therapeutic adjuvants of more active species. However, the overall therapeutic
effect may be increased if higher doses can be delivered; in this case, high-loading carriers gain interest.
Among silica-based carriers, HMSNs are the most suitable candidates, since they theoretically allow
loading in larger quantities than their porous analogues. The diverging aspects of MSNs vs. HMSNs in
peptide delivery were studied by Rahmani et al., who focused on pepstatin A, a cathepsin D inhibitor
peptide [118]. Surprisingly, the authors found two unexpected behaviors: HMSNs loaded less peptide
than typical large-pore MSNs, but their effect was higher. Therein, the authors justified such behavior
based on the release patterns observed from HMSNs, which provided a more sustained release (longer
therapeutic effect), in comparison to regular pore-expended MSNs, which showed a burst-like release.
Another promising anticancer peptide is NuBCP9 (FSRSLHSLL), which is able to bind the Bcl-2
protein, highly overexpressed in cancer cells, turning a cell protector into an apoptosis inductor [138].
Along this line, Wu et al. reported folate-targeted, large-pore MSNs able to deliver this NuBCP9
peptide into HeLa tumors in zebrafish [119]. The resulting ca. 35-nm-width MSNs with pores in the
range of 20 nm showed effective internalization into folate-positive HeLa cells, reaching up to 70%
reduction of viability when loaded with the peptide. On the other hand, these nanoparticles showed
fantastic biocompatibility, as they permitted obtaining fish survival above 80% in concentrations up to
200 µg/mL. In addition to this targeted example, this peptide was also employed in combination with a
typical chemotherapeutic. In this contribution, the authors employed ca. 30-nm MSNs with large pores
to load the peptide and an outer coating of a fifth-generation polyamidoamine (PAMAM) dendrimer
able to load DOX within the structure [120]. As a result, the nanosystem was able to co-deliver
both pro-apoptotic species to several cancer cell lines, achieving almost complete cell destruction in
concentrations up to 1 µg/mL. To validate the potential of such a combination, the authors tested the
efficiency of their nanosystem against resistant cell lines, obtaining outstanding results except for the
case of the DOX-resistant MCF-7 line. Nevertheless, these results must be carefully accounted for,
as the outermost PAMAM cationic coating may produce a decrease in overall biocompatibility.
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4.2. Immunostimulating Peptides
Although most examples of immunostimulation were reported with fully functional proteins,
the use of peptides is also possible. Along this line, Xie et al. reported the use of hollow mesoporous
silica-based nanocarriers to deliver two melanoma-derived antigen peptides: the hydrophobic
H2-Kb peptide TRP2180–188 (SVYDFFVWL) and the hydrophilic H2-Db peptide HGP10025–33
(KVPRNQWL) [121]. In order to achieve the desired double loading, the authors modified their
HMSNs with amino groups at the internal space and the mesopores with carboxylates in order to create
two different preferential locations for peptides within the HMSNs. Then, to provide adequate retention
and colloidal stability, the system was further coated with a lipid bilayer. Furthermore, on this lipid
layer, another therapeutic species was included to increase the overall effect: monophosphoryl lipid A
(MPLA), a Toll-like receptor 4 (TLR4) agonist. The resulting hollow protocells showed time-dependent
uptake by murine bone marrow-derived dendritic cells and, according to data shown, induced cell
maturation as seen by the overexpression of CD86, TNF-α, IFN-γ, IL-12, and IL-4 proteins. When the
system was tested against melanoma lung metastasis in murine models, the vaccinated animals showed
less tumor growth and creation of metastatic lymph nodes, demonstrating that the system was able to
induce an effective anticancer response in mice.
4.3. Antibacterial Peptides
Although antimicrobial peptides are one of the most promising research lines to fight
multi-resistant bacteria, their incorporation into nanocarriers was poorly studied [139]. Among the
few systems reported, the contributions made by Braun et al. can be highlighted, who studied
the best loading strategy and silica composition for the cationic antibacterial peptide LL37
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES). In their first contribution, these authors focused
on the membrane interactions betweenE. coli and several silica-based (non-porous, calcined mesoporous,
and amino-capped mesoporous) nanoparticles loaded with the LL37 peptide [122]. As expected, the
best loading profiles were obtained for the porous calcined—most negatively charged—nanoparticles.
In addition, as expected, MSNs provided an adequate protective environment for the peptide and,
hence, reduced the associated hemo- and proteolysis. At this point, it is also interesting to remark that
these authors also studied how the porous structure affected the delivery, in this case, by comparing
regular sized-MSNs with large-pore HMSNs [140]. They found that ca. 2.5-nm-pore MSNs produced a
burst release, while the HMSNs showed a more sustained release, in concordance with data obtained
by Rahmani et al. [118], suggesting that HMSNs behave better for peptide delivery.
Apart from the activation of immune cells and vaccination, the treatment of infected cells is
another big issue that could be solved by applying nanotechnology. One inspiring example was
recently reported by Tenland et al., who employed MSNs to deliver an anti-tuberculosis peptide to
infected macrophages [123]. In their work, the NZX (GFGCNGPWSEDDIQCHNHCKSIKGYKGG
YCARGGFVCKCY) peptide with a proven anti-tuberculosis effect was employed [141]. In this case,
the system was assembled by threading the peptide into the mesopores, employing previously
optimized nanoparticles [140]. The system demonstrated effective internalization into macrophages
and produced peptide release once internalized. As a result, the infecting mycobacterium could the
killed without significantly affecting host macrophages; moreover, the MSN-carried peptide showed a
longer therapeutic effect than its free form. This effect, seen in other reviewed examples, was justified
by the accumulation of nanocarriers within intracellular vacuoles, which created therapeutic reservoirs
by maintaining peptide integrity.
Apart from the delivery of antibacterial peptides, combination therapies were also recently
reported. Along this line, Zink and coworkers reported the simultaneous delivery of the melittin (MEL,
GIGAVLKVLTTGLPALISWIKRKRQQ) peptide and the antibiotic ofloxacin (OFL) with a mesoporous
silica-based assembled nanosystem [124]. In this system, the authors employed a very elegant strategy to
co-deliver the medium-size peptide together with the small antibiotic. To do so, they prepared large-pore
MSNs which were loaded with MEL and capped with aβ-cyclodextrin-modified polyethyleneimine and
Pharmaceutics 2020, 12, 432 18 of 42
ofloxacin-loaded, adamantane-modified SPION@MSNs capped by cucurbit[6]uril units. The resulting
nanoparticles were able to self-assemble and create nanogates able to maintain both drugs within
the closed pores. The system was proven to disassemble under magnetothermal induction, thereby
releasing both species, which demonstrated efficient destruction of planktonic bacteria and biofilms.
Indeed, this system demonstrated its efficiency even when embedded into implants, which were able
to prevent bacterial infection in mice.
4.4. Growth Factors
As in many other cases, peptides could also have anabolic properties. These features make
them interesting candidates for their use as cargoes in new-generation therapeutic devices aimed
at tissue growth induction or hormone therapy. The first example in this field, reported by Lin’s
group, employed MSNs to intracellularly deliver cyclic adenosine monophosphate (cAMP). To obtain
chemical responsiveness, the authors modified the MSNs with a boronic acid –B(OH)2 moiety able
to coordinate glucuronic acid moieties. The mesopores were then loaded with cAMP and closed
through glucuronate-modified insulin nanocaps [125]. The resulting system was sensitive to glucose,
as it could be disassembled by chemical displacement. As a result, this system permitted regulating
hyperglycemic levels through a dual release mechanism: Insulin to trigger glucose assimilation by
liver, and cAMP delivery to induce glycolysis. Unfortunately, this proof of concept was not further
evaluated in vivo.
More recently, Sun et al. revisited insulin delivery with MSNs. To do so, they developed
a glucose-sensitive nanodevice employing rod-like MSNs and a polymer shell able to change its
conformation upon the presence of glucose [126]. In their investigations, the authors optimized the
composition of this polymeric shell by using three different monomers: N-isopropylaminomethacrylate
(NIPAM) to provide the needed morphological shift, 3-acrylamidophenylboronic acid as a
glucose-sensitive fragment, and dextran maleate as an optional hydrophilic component. The resulting
system could be loaded with insulin at low temperatures (4 ◦C), in which the polymer adopted an
expanded conformation and closed upon heating (37 ◦C). Both reported compositions showed effective
insulin release when glucose was present; however, when pH was below 7, the polymer was not able to
shift morphology, avoiding insulin release. Although only in vitro tests were reported, the possibilities
of this model are considerable, as the incorporation of dextran may favor colloidal stability and enhance
biocompatibility, as suggested by the high cell viability values obtained. Insulin delivery was also
investigated by Zakeri-Siavashani et al., who employed SBA-15 mesoporous microparticles [127];
however, therein, the authors profited from the bigger pore size provided by these particles to achieve
higher loading and more sustained release. Although their system showed a nice insulin release
profile, the typical bigger sizes of SBA-15 particles (generally above 300 nm) limit their application in
intravenous formulations, although they may be used to create biocompatible reservoirs.
The facile aggregation of SBA-15 particles caused by their size, which makes their trafficking
through alveoli and capillaries extremely difficult, makes these materials ideal candidates for
non-systemic therapies, for example, bone replacement and tissue regeneration. In our first contribution
to the topic, we found that the osteostatin peptide, derived from parathyroid hormone-related protein
(PTHrP107–111), could be efficiently delivered using this kind of material [128]. A clear regenerative
effect was observed, which permitted recovering bone mass in peri-implant bone regeneration in
cavitary defects [129], as well as in osteoporotic subjects [130]. More recently, our investigations focused
on the combination of this peptide with osteogenic elements embedded in bioactive glasses [142,143],
finding an enhanced bone formation consequence of the exerted combination therapy.
In addition to these examples, other research groups also focused on the combination of
osteoinductive peptides with bone-forming agents. Such is the case of the model reported by
Mendes et al., which combined an osteogenic growth peptide (OGP, ALKRQGRTLYGFGG) with
hydroxyapatite in an SBA-15-based formulation [131]. Therein, the authors found a substantial
behavior difference when hydroxyapatite was present, while deeper studies on the possibilities of
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such a combination were not addressed. Another interesting combination for remineralizing bone was
reported by He and coworkers, who employed MCM-41 to prepare a nanosystem able to deliver a
BMP-2-derived peptide (KIPKASSVPTELSAISTLYL) together with dexamethasone, a potent synthetic
glucocorticoid [132]. Although, in this case, the peptide was not intended to be released, experimental
results showed that its presence exerted a clear osteogenic induction. Moreover, the system was able to
promote osteogenic differentiation on mesenchymal stem cells in vitro, as indicated by the upregulation
of alkaline phosphatase (ALP) and other bone-forming proteins. Additionally, an increased calcium
deposition was observed, demonstrating that mesoporous silica nanoparticles are adequate materials
for bone engineering.
5. Delivery of Nucleic Acids: Gene Modulation and Silencing
Gene modulation and silencing are promising strategies to efficiently treat cancer, as well as
cardiovascular or inflammatory-related diseases [20]. NAs are rapidly degraded by endonucleases
and barely internalized by cells. Therefore, the biggest challenge today is to develop an effective gene
delivery vector to transport and introduce NAs into the gene therapy target cells. These carriers must
be easy to manipulate and show non-toxic properties in vitro and in vivo.
There are two main carriers for gene delivery therapy: viral and non-viral vector platforms [144].
For non-pathogenic viruses (retro and adenovirus), the most used platforms are viral vectors, but they
present some limitations such as high cost and manipulation, immune response, or inadequate
accessibility of genetic cargo internalized by cells [144]. Currently, research groups are focusing their
efforts on the improvement of cheaper and easier preparation of non-viral platforms as cation polymers,
liposomes, or inorganic porous nanoparticles such as MSNs [145]. In this respect, PEI is a widely used
polycation in gene delivery systems due to its amino protonation improving gene delivery [20,144,145].
Liposomes are also commonly applied to enhance the cell internalization of NAs. Both polycations and
liposomes present some limitations for therapeutic applications related to their molecular weight or
disadvantageous gene escape and physicochemical instability, respectively [20,144,145]. Nevertheless,
MSNs showed optimal properties for intracellular delivery of NAs due to their easy manipulation,
high loading capacity into the mesopores, surface functionalization, and non-toxicity characteristics [20].
In addition, MSNs can be combined with polycations and other therapeutic drugs for personalized
treatment related to cancer and other diseases.
In this regard, plasmid DNAs (pDNAs) are the most widely used gene therapy material to treat
different diseases [20,144,145], although there is increasing interest in small interfering RNAs (siRNAs)
and microRNAs (miRNAs) for therapeutic application. In this section, we focus on NA-loaded (DNA,
siRNA, and miRNA) MSN-based drug delivery systems, as shown in Table 3 and Figure 5.
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Table 3. Examples of different therapeutic nucleic acids delivered by silica-based nanocarriers.
Nucleic Acid Carrier Type NA Location Loading Strategy Cell Line(s) In Vivo Application Reference
DNA
pDNA MSNs Surface Adsorption Neuro-2A None Cancer [146]
pDNA MSNs Surface Adsorption HEPA-1 None Cancer [147]
dsDNA MSNs Surface Adsorption HeLa None Cancer [148]
dsDNA MSNs Surface Adsorption HL-60 None Cancer [149]
pDNA IDMSMs Surface Adsorption QGY-7703 Mice Cancer [150]
ssDNA MSNs Surface Disulfide bondMaleimide MCF-7 None Cancer [151]
dsDNA HMSNs Surface Adsorption MCF-7, A549,HepG2 None Cancer [152]
ssDNA MSNs Surface Adsorption MDA-MB-231 Mice Cancer [153]
ssDNA MSNs Surface Adsorption MCF-7, K-562,U2OS Mice Cancer [154]
pDNA MSNs Surface Adsorption 293T, RAW264.7 Mice Hepatitis B [155]
siRNA
PKM2 MSNs Surface Adsorption MDA-MB-231 Mice Cancer [156]
Cell-killing MSNs Mesopores Adsorption MDA-MB-231 None Cancer [157]
HER2 MSNs Surface Adsorption BT474 None Cancer [158]
TGFβR-1 MSNs Surface Adsorption RT3 Mice Cancer [159]
MDR1 MSNs Surface Adsorption CAL27 None Cancer [160]
MDR1 MSNs Surface Adsorption KBV Mice Cancer [161]
Bcl-2 MSNs Surface Adsorption SKOV-3, MCF-7 None Cancer [162]
Bcl-2 MSNs Surface Adsorption SKOV-3 Mice Cancer [163]
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Table 3. Cont.
Nucleic Acid Carrier Type NA Location Loading Strategy Cell Line(s) In Vivo Application Reference
siRNA
TWIST MSNs Surface Adsorption F2, Ovcar8 Mice Cancer [164]
VEGF MSNs Surface Adsorption HeLa, HepG2 None Cancer [165]
VEGF MSNs Surface Adsorption HepG2, Huh7 None Cancer [166]
HSP47 MSNs Surface Adsorption PMDF Mice Fibrosis [167]
TnC MSNs Surface Adsorption rHSCs, mHSCs None Fibrosis [168]
COLL1A1 MSNs Surface Adsorption HDFs Rat Tissueregeneration [169]
SOST MSNs Surface Adsorption MEF, HeLa Mice Osteoporosis [170]
miRNA
miR-155 MSNs Mesopores Adsorption SW480 Mice Cancer [171]
miR-328 MSNs Mesopores Adsorption SW480, SW620,HT-29, Lovo, Caco-2 Mice Cancer [172]
miR-34a
miR-10b MSNs Mesopores Adsorption
MDA-MB-231,
MDA-MB-468 Mice Cancer [173]
miR-26a MSNs Mesopores Adsorption rBMSCs None Tissueregeneration [174]
miR-200c
siPlk1 MSNs Mesopores Adsorption MDA-MB-231 Mice Cancer [175]
Abbreviations: IDMSN: imidazole dendritic mesoporous silica nanoparticles; PKM2: glycolytic enzyme pyruvate kinase; HER2: human epidermal growth factor receptor 2; TGFβR-1:
transforming growth factor, beta receptor I; MDR1: multidrug resistance protein 1; Bcl-2: B-cell lymphoma 2; VEGF: vascular endothelial growth factor; HSP47: heat-shock protein 47; TnC:
tenascin-C; COLL1A1: collagen type I; PMDFs: primary mouse dermal fibroblasts; HSCs: human stem cells; HDFs: human dermal fibroblasts; MEF: mouse embryonic fibroblastic cells;
rBMSCs: rat bone marrow stromal cells.
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5.1. DNA
As we previously mentioned, MSNs can be functionalized with PEIs for better DNA molecule
adsorption and, thus, for a more effective intracellular delivery, protecting NAs from endonuclease
degradation due to their positive charge. These positive charges interact with negatively charged cell
membranes, inducing higher cell internalization rates and cell death. For example, Zarei et al. [146]
developed a functionalized nanosystem based on phosphonate MSNs-PEI loaded with a lysosomotropic
factor, chloroquine (CQ), complexed with plasmid DNA. The resulting cell internalization and viability
of this pDNA-MSN-PEI was analyzed with the fluorescent protein plasmid (pGFP (green fluorescent
protein)), showing a significant increase in transfection of pGFP into the mouse neuroblastoma cell
line Neuro-2A. In this respect, Xia et al. [147] proposed the use of a cationic MSN-PEI nanocarrier
with a potential therapeutic application. The resulting cationic surface of MSNs facilitated the DNA
attachment in order to balance the cationic 10-kDa PEI and, hence, achieve nontoxic effects and higher
cellular uptake rates. This nanosystem was loaded with a plasmid DNA (pEGFP) and siRNA construct
that was capable of knocking down GFP expression in hepatocellular carcinoma mouse (HEPA-1)
cells, with a fluorescent GFP expression of 70% in these cells. In addition, the authors loaded the
cationic MSN-PEI nanocarrier with paclitaxel, a hydrophobic anti-tumoral drug used in pancreatic
tumor treatment, increasing the cell internalization and delivery of this drug in HEPA-1 cells. On the
other hand, Song et al. [29] demonstrated that controlling the nanotopography of MSNs as pDNA
vectors had an influence on the transfection efficacy. For example, ambutan-like MSNs-PEI with spiky
surfaces showed pDNA-binding capability and a transfection efficacy of 88% in HEK-293T cells, which
was a higher rate compared with other MSNs systems. In addition, the authors demonstrated that
these types of surface spikes of MSNs induced a continuous open space with two objectives: binding
DNA chains through multivalent interactions and protecting the gene cargo covered in the spiky layer
against enzymatic degradation, without negative effects on transfection rates. These results indicated
that this nanosystem is an interesting approach as a non-viral vector for effective gene delivery.
Pharmaceutics 2020, 12, 432 23 of 42
In a study by Wang et al. [148], an MSN based nanoplatform functionalized with a DNA gate
was evaluated in vitro. In this report, the authors developed a fluorometric method for adenosine
triphosphate (ATP) recognition using rolling circle amplification (RCA) consisting of proximity
ligation-mediated amplification. In addition, the nanosystem was functionalized with graphene
oxide modified with folic acid (FA) as a DNA vehicle and loaded with DOX, to evaluate the control
release efficacy in HeLa tumoral cells. Following the RCA process, long DNA chains that contained
a complementary strand to the DNA at the gate permitted dehybridizing such a nanogate and
producing DOX release into tumoral cells. This nanoplatform was effectively internalized by the FA
receptor, upregulated in those tumoral cells, while the DOX release induced increased cell toxicity
compared with control systems, improving the targeted cancer therapeutics on these HeLa cells.
In another study by Wang et al. [149], a DNA-capped MSN nanocarrier loaded with DOX for tumor
marker-triggered on-demand drug release was developed and evaluated in vitro. As a first step,
a DNA biomolecular gate adsorbed on the MSN–NH2 was developed at neutral pH via electrostatic
adsorption. In the absence of a stimulus, the pores were locked, and it was not possible to release
the drug. However, when the nanosystem recognized the internal stimulus (survivin messenger
RNA (mRNA) or miR-21, overexpressed biomarkers in cancer), the DNA caps were removed from
the MSNs, allowing DOX release. This stimulus-responsive behavior was confirmed by different
microscopy techniques in cell-acute myeloblastic leukemia (HL-60) cells. This nanocarrier was
effectively internalized by these cells, releasing DOX cargo into the cytoplasm and inducing significant
cell death. Therefore, this nanoplatform is a very useful novel system for both imaging diagnosis
and therapeutic controlled drug delivery applications. In this regard, Li et al. [150] designed and
evaluated another anti-tumoral and gene drug co-delivery nanosystem with on-demand release
properties in vitro and in vivo. For this purpose, the authors developed dendritic MSNs modified with
imidazole groups employing a Schiff-base imine linkage, which permitted loading DOX within the
pores and electrostatically depositing the survivin short hairpin RNA (shRNA)-expressing plasmid
(iSur-pDNA). The imidazole functionalization triggered efficient endosomal escape, improving the
accumulation of iSur-pDNA and gene knockdown efficacy. Such nanosystems were successfully
internalized by QGY-7703 hepatoma cells and decreased tumoral cell viability in vitro, due to the
pH-sensitive co-delivery of DOX and iSur-pDNA. In addition, this nanoplatform induced tumor
growth reduction in H-22 tumor-bearing mice, indicating that it could be a promising nanocarrier for
co-delivery cancer treatment.
On the other hand, aptamers are short single-stranded oligonucleotides with high affinity and
specificity to several molecule targets, and they exhibit potential properties as therapeutic and
diagnostic factors in different diseases [176]. In this regard, Sun et al. [151] developed an MSN-based
nanocarrier with different DNA molecules on the surface for self-assembly. For the controlled delivery of
anti-tumoral drug cargo (DOX), the authors used an aptamer oligonucleotide as a gatekeeper and other
oligonucleotides on the MSN surface to allow DNA-guided immobilization bearing single-stranded
capture oligonucleotides. This nanovalve induced an increase in cell adhesion rates in MCF-7
adenocarcinoma cells, with an efficient triggered release of DOX drug in these cells. The DNA-directed
self-assembly aptamer-based nanosystem is efficient in surface-bound monolayers and can be used as a
delivery system for different applications and treatments, allowing site-specific delivery of anti-tumoral
drugs. In the same way, Li et al. [152] developed a dual multi-locked DNA valve HMSN-based
nanosystem to intracellular cancer-related mRNAs for controlled DOX drug release. The upregulated
endogenous targeted mRNAs (K1 and GalNAc-T mRNAs) were able to dehybridize the multi-locked
DNA valves and open the pores to release DOX. As a result, a synergic effect was obtained, caused by
the intratumoral delivery of the drug together with the depletion of TK1 mRNA, implicated in cell
division as a tumor growth factor, and GalNAc-T, upregulated in several tumoral cells. The nanocarrier
was evaluated in vitro in different cancer cells, inducing higher rates of cytotoxicity compared to
non-tumoral cells. In an in vivo study, Pascual et al. [153] designed another novel non-viral drug
delivery and diagnostic nanocarrier based on a capped MSN-NH2 hybrid platform, which was
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loaded with DOX and gated with Mucin 1 (MUC1) aptamer (S-apMUC1). MUC1 is a protein present
in the cell surface and upregulated in breast cancer cells. The S-apMUC1-MSNs nanosystem was
efficiently and specifically internalized only by tumoral MDA-MB-231 cells related to MUC1 receptor
overexpression of these cells. After S-apMUC1-MSNs internalization by tumoral cells, the DOX cargo
was released into the cytoplasm of tumoral cells, inducing a decrease in cell viability. This nanoplatform
exhibited reduced cargo release when DNAse I was not present. In vivo, S-apMUC1-MSNs were
radionuclide-labeled with 99Tc for a radio-imaging study in MDA-MB-231 tumor-bearing Balb/c mice.
S1-apMUC1-Tc displayed significant tumor signaling and accumulation in these mice. These results
suggest that MSN nanosystems capped with aptamers showing radiopharmaceutical properties are
promising hybrid nanomaterials in the clinical context.
Of particular interest is a study by Srivastava et al. [154], where the authors proposed a novel
telomerase-responsive delivery of DOX loaded in an MSN nanosystem against telomerase-positive
tumoral cells. DOX loading was performed using a telomeric repeat complementary sequence and
a telomerase substrate primer sequence, allowing controlled release in MCF-7 cancer cells. This
functionalized nanocarrier was efficiently internalized, and it significantly reduced the tumoral
cell viability, with an inhibition of function when a specific telomerase inhibitor was present. This
oligo-wrapped nanoprobe specific for telomerase was used in a telomerase-positive Dalton’s lymphoma
mice model. The nanosystem induced a significant inhibition of tumors, enhanced survival, and
re-established histopathological parameters, including neo-angiogenesis.
Furthermore, DNA vaccination was proven to provide an immune response to viruses or infectious
diseases [177]. In this regard, Wang et al. [155] developed a layered double hydroxide (LDH) MSN
nanocarrier as a vaccine delivery platform and immune stimulant, using a GFP expression plasmid as
model DNA. The pDNA-MSN-LDH nanosystem showed high internalization rates in monocyte-derived
dendritic cells (MDDCs) and stimulated macrophage activation via nuclear factor kappa B (NF-κB)
signaling pathway, increasing IFN-γ, IL-6, CD86, and major histocompatibility complex class I (MHC-I).
In vivo, the nanocarrier immunized BALB/c mice, indicating that the DNA vaccine-MSN-LDH system
increased the serum antibody response and promoted T-cell proliferation, skewing T helper to Th1
polarization. Taken together, these results indicated that MSN-LDH nanosystems could operate as a
potential non-viral gene delivery platform.
5.2. siRNAs
Small interfering RNA (siRNA) are highly potent, short, double-stranded RNA molecules
(20–25 bp) used in gene-based therapy of different diseases that can be delivered in a sustained
manner [178]. Moreover, siRNAs are anti-cancer targets because they can modify the expression of
pro-apoptotic oncogenes and cell-cycle key regulators. However, siRNAs have a very short half-life
and poor cell internalization capability [178]. In this regard, MSNs attracted pronounced consideration
for the intracellular delivery of NAs due to their high loading capacity into the mesopores and surfaces.
Polycations such as PEI combined onto the surface of MSNs permit a more stable encapsulation, loading,
controlled release, and intracellular internalization of potential siRNA cargoes [178]. In addition,
positively charged amine-rich nanosystems are required for a better result in siRNA/MSN cellular
uptake rates [178]. Future in vivo efforts are necessary to validate the tissue-specific siRNA therapeutic
efficacy using imaging techniques to analyze MSN biodistribution at the whole-body level. On the
other hand, it is mandatory to find nanosystems able to efficiently deliver those therapeutic siRNAs
in vivo with enough efficiency, as well as with protective features against nucleases, able to enhance
their gene-silencing capabilities at the target tissues.
In this respect, Shen et al. [156] developed a universal siRNA multi-component system carrier
based on MSNs functionalized with cyclodextrin-grafted polyethyleneimine (CP). CP offers a
positive charge to improve the siRNA loading on MSNs through electrostatic interaction, allowing
endosomal escape. To analyze the effectiveness of the proposed delivery system, an siRNA of the M2
isoform of the glycolytic enzyme pyruvate kinase (PKM2) was used, due to it being overexpressed
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in several cancer types. Firstly, siRNA-loaded CP-MSNs were positively evaluated in vitro in
MDA-MB-231 human breast cancer cells with higher rates of cellular internalization and gene
silencing capability. The nanosystem showed specific tumor accumulation and gene silencing in an
orthotopic mouse model of MDA-MB-231 cells, inhibiting tumor cell growth, invasion, and migration.
Prabhakar et al. [157] designed a new nanosystem based on MSNs with expanded mesopores and
pore–surface-hyperbranched PEI tethered with redox-cleavable organic linkers that could carry
high concentrations of siRNAs. This stimulus-responsive nanosystem was highly internalized by
MDA-MB-231 cells, releasing the cell-killing siRNA as cargo into the cytoplasm, followed by endosomal
escape triggered by the intracellular redox situation, with high efficiency in long-term gene knockdown
for several days. In addition, long-term stability of therapeutic nanosystems is mandatory to provide
personalized medicine. In this respect, lyophilization or freeze-drying are useful and common methods
to ensure this aim. Ngamcherdtrakul et al. [158] successfully reported a lyophilized nanosystem
consisting of MSNs modified with cationic polymers (PEI), PEG, and antibody (trastuzumab), which
was loaded with a human epidermal growth factor receptor 2 (HER2) siRNA upon reconstitution.
This nanosystem was successfully internalized by HER2+ human breast cancer cells, BT474, decreasing
their viability; it maintained a cake-like structure and retained hydrodynamic size, charge, siRNA
loading ability, and silencing efficacy. With the tested method, the lyophilized nanocarrier can be
stored stably for eight weeks at 4 ◦C and at least six months at −20 ◦C.
Oral cancer is the seventh most frequent cancer and the ninth most frequent cause of death in
the world [179]. About 90% of oral cancer is of squamous cell carcinoma type (SCC) [179]. Currently,
surgery and radiation, combined or not with chemotherapy, are the main treatments, but this approach
presents several limitations due to multidrug resistance; thus, new therapeutic drugs must be evaluated.
Lio et al. [159] developed a topical formulation for the transdermal delivery of siRNA built on MSNs
for the treatment of skin disorders. In this regard, transforming growth factor beta receptor I (TGFβR-1)
is overexpressed in patients with skin SCC, and the anti-tumor effects of TGFβR-1 inhibitors were
proven in several types of cancer. The nanosystem was built by loading TGFβR-1 siRNA into the
pores of MSNs and further coating the resulting particle with a layer of poly-l-lysine (PLL) to improve
transdermal delivery. The tested platform demonstrated positive cellular uptake rates and detection
of specific gene biomarkers in human SCC cells in vitro. This system induced a topical delivery of
TGFβR-1 siRNA targeting the SCC in a mouse xenograft model, decreasing the TGFβR-1 siRNA levels
and reducing tumor volume. These results indicated that this platform is a promising non-invasive
transdermal drug delivery system. Moreover, multidrug resistance plays an important role in the
failure of oral cancer chemotherapy. In this sense, in a study by Wang et al. [160], a novel MSN loaded
with both multidrug resistance protein 1 (MDR1) siRNA and DOX was evaluated in vitro and in vivo
to directly kill tumor cells without the effect of multidrug resistance. MSNP-PEI@siRNA loaded with
DOX was efficiently transfected into human oral squamous carcinoma DOX-resistant (KBV) cells,
decreasing the gene expression of MDR1 and increasing the apoptosis of these cells. This nanocarrier
significantly reduced the tumor size and decelerated tumor growth rate in vivo, showing a huge
potential therapeutic application for multidrug-resistant cancer. On the other hand, Shi et al. [161]
developed hyaluronic acid (HA)-assembled MSNs nanosystems loaded with MDR1 siRNA and protein
MutT homolog 1 (MTH1) inhibitor TH287. Downregulation of MTH1 protein expression increased
oxidative stress levels and significantly decreased tumor survival and proliferation. TH287 is a potent
small molecule that inhibits the MTH1 protein, and it could act as a potential chemotherapeutic drug.
The HA-MSNs nanosystem was successfully internalized by CAL27 cancer cells, inducing a high rate
of cell apoptosis when TH287 and MDR1 siRNA were present. In vivo, this nanocarrier reduced the
tumor growth compared with untreated control and free TH287 in male Balb/c mice. These results
suggest that HA-MSN-based nanosystems are a promising vehicle to control the delivery of MDR1
siRNA and TH287, with a possible combination with other therapeutic agents for oral cancer treatment.
Regarding multidrug resistance as a persistent limitation for cancer treatment, Pan et al. [162]
proposed a novel pH-responsive delivery nanosystem based on carboxylated MSNs (MSN-COOH)
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with a zeolitic imidazole framework-8 (ZIF-8) film synthesized for pore blocking and efficient loading
of anti-apoptotic B-cell lymphoma 2 (Bcl-2) siRNA. The nanosystem developed was efficiently
internalized by MCF-7/ADR and SKOV-3/ADR tumoral cells. The ZIF-8 film can be degraded in the
acidic endo-lysosome and trigger the intracellular release of both siRNAs and potential antitumor drugs,
decreasing cancer cell proliferation. In this regard, Choi et al. [163] developed a new biodegradable
and biocompatible amine-free, neutral MSN-based nanocarrier for siRNA delivery. In this study, Bcl-2
siRNA was loaded via a calcium ion (Ca2+)-mediated interconnection between phosphates of siRNA
and surface silicates of MSNs, reducing the risk of amine-related cytotoxicity and immunogenicity.
This nanosystem showed positive results in internalization rates in tumoral SKOV-3 cells, inducing a
significant decrease in cell viability when the siRNA was released, compared with MSNs or siRNA
alone. This reduction in tumoral cell proliferation was dramatically enhanced when the nanocarrier
was loaded with DOX. The therapeutic potential of the co-delivery system was also analyzed in SKOV3
xenografts in nude mice. The authors found that co-delivery of Bcl-2-siRNA and DOX MSNs-Ca2+
reduced tumor volume with an inhibition rate of 72%, higher than MSNs-Ca2+ loaded with DOX and
MSNs-Ca2+ with siRNA. The results indicated that Ca2+-bound MSNs can act as an siRNA nanocarrier
with a less toxic, more effective, and safer siRNA potential clinical application. On the other hand,
patients with epithelial ovarian cancer (EOC) metastases relapse after initial effective chemotherapy
treatment due to multiple drug resistance. In order to resolve this problem, Shahin et al. [164]
proposed a novel nanoparticle delivery platform to reverse chemoresistance based on HA-MSNs
loaded with TWIST siRNA. Hyaluronic acid (HA) is a ligand for CD44, which is overexpressed and
correlates with worse prognosis in EOC. TWIST is a key protein implicated in epithelial–mesenchymal
transition, cancer metastasis, angiogenesis, and drug resistance. The developed nanocarrier was
successfully internalized in vitro by F2 and Ovcar8 cell lines, inducing a sustained TWIST gene
knockdown. MSN-HA@siRNA showed safety and specific tumor targeting in an EOC mouse model.
Mice treated with the complete nanosystem induced significant tumor reduction, and, when the
authors combined this nanocarrier with cisplatin, the reduction of tumor growth was greater compared
with the corresponding control groups.
For the metastatic spread of cancer, growth of the vascular network is a critical event [29]. Vascular
endothelial growth factor (VEGF) is a glycoprotein and key mediator of angiogenesis in tumoral
cells [180]. Keeping this in mind, Zheng et al. [165] proposed a new nanocarrier based on MSNs
functionalized with FA-targeted tumoral cells and co-loading of VEGF siRNA and ursolic acid (UA),
a pentacyclic triterpenoid with anticancer efficacy. HeLa (FA receptor-overexpressed) and HepG2
tumoral cell lines were used to analyze the MSN-FA-UA@siRNA nanosystems in vitro. The MSN-FA
nanocarrier enhanced transfection efficiency and siVEGF stability, improving the targeted antitumoral
efficacy of siVEGF and UA, with a significant decrease in cancer-related VEGF protein levels in HeLa
cells. In this sense, the same authors [166] developed an alternative MSN nanosystem consisting of an
asialoglycoprotein receptor (ASGPR)-targeting drug delivery system for co-delivery of siVEGF and
sorafenib (SO), a multi-kinase inhibitor that can target VEGF for the inhibition of tumor growth and
neo-angiogenesis in hepatocellular carcinoma (HCC). Lactobionic acid (LA) is derived from lactose
oxidation, and it was able to effectively target human HCC. In addition, ASGPR is overexpressed
in several types of cancer cells, facilitating hepatic infection, and it is specifically recognized by
glycoproteins which bind with it. The MSN-LA-SO@siVEGF nanocarrier induced synthesis (S) phase
cell-cycle arrest, increasing the anti-cancer efficacy (cell apoptosis) of SO and siVEGF through the
active targeting of LA in ASGPR-overexpressing Huh7 tumoral cells. Furthermore, this nanosystem
enhanced the siVEGF transfection efficiency and inhibited the expression of angiogenesis-related VEGF
proteins in these tumoral cells. Taking both studies together, these types of functionalized MSN-based
nanosystems could be potential nanocarriers for targeted delivery of anti-tumoral drugs and VEGF
siRNAs to improve anti-tumor capability.
On the other hand, fibrotic diseases are related to augmented oxidative stress and upregulation
of pro-fibrotic genes [181]. Oxygen species (ROS), nicotinamide adenine dinucleotide phosphate
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(NADPH) oxidase 4 (NOX4) and heat-shock protein 47 (HSP47) are implicated in this disease [181],
producing disproportionate collagen synthesis. Morry et al. [167] proposed an MSN platform with
PEI and PEG coating that effectively delivered HSP47 siRNA in vitro and in vivo. This nanocarrier
induced a knockdown of the HSP47 gene and a decrease in ROS and NOX4 levels in an in vitro model
of fibrosis based on TGF-β-stimulated fibroblasts. Intradermal administration of MSNs@siHSP47
successfully decreased HSP47 protein levels in a bleomycin-induced scleroderma mouse model in vivo,
reducing ROS production and different pro-fibrotic markers. These nanocarriers could be a very
interesting platform to treat both fibrotic and inflammation diseases. On the other hand, it is necessary
to develop anti-fibrotic drugs for chronic liver fibrotic diseases. Hepatic stellate cell (HSC) activation is
present in the progression of liver fibrosis, secreting extracellular matrix proteins as tenascin-C (TnC).
Vivero-Escoto et al. [168] proposed an MSN@siTnC based nanosystem as a favorable alternative to
evaluate the siRNA therapy of chronic liver disease in preclinical trials. This novel nanocarrier was
successfully internalized by human stem cells in vitro and produced a downregulation in TnC mRNA
and protein levels, inducing a decrease in inflammatory cytokine expression by macrophages and
hepatoma migration. These promising results must be tested in a liver fibrosis in vivo model.
As demonstrated in this section, siRNA-MSN based nanosystems were widely studied and showed
a high efficiency in silencing genes and reducing tumoral growth related to cancer processes in vivo.
Nevertheless, in tissue engineering applications, scaffold-mediated delivery is desired to achieve local
and sustained release of drugs. In this respect, Pinese et al. [169] developed an MSN-PEI@siRNA
nanocarrier delivered from electrospun scaffolds via surface adsorption and nanofiber encapsulation.
These nanosystems were either combined with the surfaces of nanofiber substrates or directly
encapsulated. MSN-PEI@siRNA coated scaffolds offered sustained availability of siRNA for at least
30 days and five months in the case of MSN-PEI@siRNA-encapsulated scaffolds within the electrospun
fibers in human dermal fibroblasts cells in vitro. The scaffolds showed excellent bifunctionality in vitro
and in vivo by targeting collagen type I (COLL1A1) as a target gene to reduce fibrous capsule formation.
These platforms were subcutaneously implanted in a rat model in vivo and COLL1A1 siRNA/MSN-PEI
induced a reduction of 45.8% in fibrous capsule formation after four weeks compared to negative
siRNA treatment. This method improved siRNA internalization rates and sustained targeted protein
silencing in vitro and in vivo. The nanoplatform proposed by these authors can be used to release and
internalize siRNA/miRNA combined with other specific low-molecular-weight drugs in long-term
tissue engineering applications and cancer. In addition, the current pharmacological therapy of bone
diseases such as osteoporosis presents several limitations related to bioavailability and toxicity. In this
sense, gene knockdown through siRNA delivery received great attention as a promising treatment in
osteoporosis [182]. In a recent study by Mora-Raimundo et al. [170], a nanosystem based on MSN-PEI,
which can effectively deliver SOST siRNA and osteostatin inside cells, was evaluated in vitro and
in vivo. The SOST gene inhibits the Wnt signaling pathway, decreasing osteoblast differentiation,
whereas osteostatin is a pentapeptide with osteogenic and anti-osteoclastic properties [183]. SOST
siRNA/MSN-PEI loaded with osteostatin induced a dramatic suppression of SOST gene expression in
mouse embryonic fibroblastic cells with the consequent upregulation of several osteogenic markers
with a synergistic effect. In vivo, the complete nanosystem was injected in the femoral bone marrow of
ovariectomized mice, and the results were in concordance with in vitro studies, knocking down SOST
and upregulating the osteogenic marker levels in a synergistic manner. The nanoplatform proposed by
these authors was able to transport, co-deliver, and internalize SOST siRNA and osteostatin in cells,
preserving its activity and achieving an effective silencing effect.
5.3. miRNAs
MiRNAs are small endogenous noncoding RNA molecules (17–25 nucleotides) that act as
regulators of gene expression and downregulate target proteins via miRNA degradation or translational
inhibition [184]. The aberrant expression of miRNAs in several cancers is associated with several
mechanisms such as cellular differentiation, proliferation, survival, and apoptosis [184,185]. MiRNAs
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can accomplish a gene knockdown effect by regulating multiple miRNAs compared to siRNA, which
is very useful when treating complex multifactorial diseases such as cancer [184,185]. Several drugs
based on miRNAs were used in clinical trials in cancer [186]; however, the effective and safe delivery
of anti-miRNAs or miRNA mimics is a key challenge for clinical applications.
Regarding these objectives, Li et al. [171] proposed a novel nanosystem based on MSN
functionalized with polymerized dopamine (PDA) and AS1411 aptamer loaded with microRNA-155
(anti-miRNA-loaded MSN@PDA-Apt) for the specific treatment of colorectal cancer (CRC).
Upregulation of miR-155 (oncogenic microRNA) was found in several cancer-related pathways,
including in CRC. Firstly, the authors demonstrated that nuclear factor kappa B (NF-κB), an important
transcription factor with a crucial role in the process of tumor growth, has a positive feedback loop with
miR-155 in vitro and in CRC tissues. MSNs-anti-miR-155@PDA-Apt decreased miR-155 expression
in SW480 cells and successfully targeted the CRC tumor, leading to gene knockdown and tumor
growth reduction, thanks to both active targeting of AS1411 aptamer and passive targeting of the
EPR effect. In addition, the same authors [172] explored the miR-328 pathway and developed a new
pH-responsive nanoplatform consisting of MSNs-miRNA-328 decorated with PDA, a cell adhesion
molecule aptamer, and bevacizumab (MSNs-miR-328@PDA-PEG-Apt-Bev) for the dual-targeting
treatment of CRC. MiR-328 is a tumor suppressor downregulated in several human cancers, including
CRC, and it is correlated with drug resistance. The authors demonstrated for the first time that
CPTP, a ubiquitously expressed lipid transfer protein associated with inflammation and CRC, is a
direct target of miR-328. MSNs-miR-328@PDA-PEG-Apt-Bev increased miR-328 levels and inhibited
CPTP expression in SW480 cells, increasing binding ability and showing much higher cytotoxicity
in vitro and in vivo. In addition, this nanoplatform showed efficient gene silencing and tumor growth
inhibition of the target tumor in a SW480 xenograft mouse tumor model in vivo. Taken together, these
results indicate that the MSN-based functionalized nanoplatforms reported herein show promise for
miRNA therapy in cancer, specifically CRC. In a recent study by Ahir et al. [173], a nanosystem based
on MSN-HA@miRNA with an appended PEG–poly(lactic-co-glycolic acid) (PLGA) polymer to target
triple-negative breast cancer (TNBC) was evaluated in vitro and in vivo. In this context, miR-34a is
downregulated and miR-10b is upregulated in TNBC disease, inducing tumorigenesis and metastatic
dissemination. These authors proposed the MSN nanocarrier for co-delivery of miR-34a-mimic and
antisense-miR-10b, targeting the CD44 receptor. In vitro, this nanosystem showed positive results in
terms of cellular internalization rates, release profile, and a subsequent pro-apoptosis effect in human
mammary carcinoma cell lines (MDAMB-231 and MDAMB-468). In vivo studies exhibited a high
specificity in TNBC tumor targeting, leading to effective tumor growth reduction and metastasis delay
in mice.
As previously mentioned, MSN nanosystems emerged as a promising bone regeneration
methodology in bone tissue engineering. In this regard, Yan et al. [174] developed a novel miR-26a
delivery nanosystem based on MSNs. MiR-26a was confirmed to regulate several pathways of
osteogenic differentiation and promote bone regeneration. The authors demonstrated the protection
effectiveness of the vectors to the miRNA and the positive internalization rates in rat bone marrow
stromal cells (BMSCs) in vitro, releasing miR-26a into the cytoplasm without cytotoxicity effects. This
nanosystem promoted stem-cell osteogenic differentiation, inducing an increase in alkaline phosphatase
activity and mineralization, as well as in several genes and proteins implicated in osteogenesis in
BMSCs. The nanocarrier proposed by these authors provides new methods and strategies for the
delivery of mRNAs in bone tissue engineering, but it is necessary to further validate them in vivo.
On the other hand, a combined siRNA/miRNA therapy would be a very interesting approach,
especially for cancer treatment, targeting multiple disease-related pathways and silencing specific genes.
Currently, the use of this combination in clinical studies shows several limitations such as the availability
of safe and effective systemic delivery nanocarriers with efficient tumor penetration. In this respect,
Wang et al. [175] developed multifunctional tumor-penetrating MSNs for co-delivery of siRNA (siPlk1)
and miRNA (miR-200c), upregulated in several types of tumor and implicated in cancer development
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and progression. In addition, the authors functionalized the nanosystem to facilitate endosomal scape
using a photosensitizer indocyanine green (ICG) and surface conjugation of the iRGD peptide to allow
deep tumor penetration. The complete nanosystem induced an increase in internalization rates in
MDA-MB-231 cells and three-dimensional (3D) tumor spheroids in vitro, whereas ROS produced by
ICG upon light irradiation induced the endosomal scape of the siRNA/miRNA into the cytoplasm with
a deleterious effect on cell viability. In vivo, a significant reduction in tumor growth and metastasis
upon short-light irradiation was found when the nanosystem was intravenously administrated in mice
with metastatic breast cancer.
6. Delivery of Glycan-Based Biomolecules
Beyond the use of proteins, peptides, and nucleotides, glycan-based structures were also
successfully employed in MSN-based delivery. Among them, the most recurrent examples are
reported with heparin, chondroitin sulfate (CS), chitosan, and HA. Those compounds, apart from
being important components of structural matrices, are known to affect many biochemical processes.
For instance, HA is a valuable targeting element for the development of new therapeutic tools, as it is
able to interact with CD44 and CD168, which are upregulated in many cancerous cells and are closely
related to cell adhesion and migration in metastases [187,188].
Similarly, chitosan [188–190] and chondroitin sulfate [191–193] were employed for the development
of high colloidally stable and biocompatible nanosystems with certain targeting capabilities. Moreover,
as both substances are important structural components of extracellular matrices on vertebrates and
crustaceans, they can act as bioactive components for tissue regeneration. Such was the case in the
contributions by Kavya et al. [194] and Porgham Daryasari et al. [195], who employed those elements
to induce osteogenesis through two different approaches. In the first approach, Kavya et al. designed a
crosslinked chitosan/CS scaffold reinforced with nanometric SiO2. In this system, the presence of silica
permitted improving the mechanical properties and obtaining slower degradation, while the glycans
permitted obtaining an adequate moisture swelling for creating a favorable environment for cell
proliferation [194]. In the article by Porgham Daryasari et al., the authors employed chitosan-coated,
dexamethasone-loaded MSNs as a bioactive component in a poly-l-lactic acid scaffold. The system
was proven to induce osteogenic differentiation of human adipose stem cells according to the ALP
activity [195]. Although both models offered promising results, the absence of osteoregeneration
experiments in vivo makes these materials a mere design exercise, in which the presence of glycans
is not completely justified. Apart from its use as a stabilizer, CS was also successfully employed as
a functional coating able to interact with blood lipoproteins through a double effect: electrostatic
interaction plus saccharide recognition [196]. Although these CS-modified dendritic MSNs permitted
selectively binding and isolating low-density lipoproteins (LDL) for analytical purposes, the potential
of such a nanosystem as a therapeutic agent is of enormous interest, as it may enable an interesting
therapeutic effect against hypercholesterolemia and blood vessel atheromatosis.
Heparin is a highly sulfated, negatively charged glycosaminoglycan with outstanding properties
as an anticoagulant. Beyond injectable applications, heparin is employed as an anticoagulant surface in
medical devices like test tubes and dialysis machines. Regarding additional uses in combination with
mesoporous silica, its capacity as a targeting moiety was also described against human hepatocyte
carcinoma HepG2 [197,198] and HUVEC cell lines [198].
Additionally, as a consequence of its anticoagulant effect, some investigations focused on improving
its release profile from silica-based carriers as nanodepots. Along this line, the research articles authored
by Zhu and coworkers performed two systematic studies on how different types of mesoporous silica,
with varying pore sizes and functionalization, affected the loading-release process [199,200]. Based
on their results, the authors established that a slight pore enlargement of MCM-41 yielded better
adsorption and release. Indeed, they also demonstrated that the presence of amino groups in the
mesopores increased the amount of heparin adsorbed, albeit at the expense of slowing down the
release [199]. With regard to SBA-15, they found that, apart from pore size and charge, the presence
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of rough pore surfaces caused by carbonaceous deposits upon calcination boosted both the retention
and the release of heparin, improving the performance of such a material and enabling access to
better-performing nanodepots.
Apart from its use as a drug delivery agent, there are examples of heparin-loaded silica-based
materials used as anticoagulant coatings for medical devices. For example, Wei et al. reported the
use of SBA-15 to prepare a heparin-releasing anticoagulant coating [201]. Their system employed
amino-modified mesopores to favor heparin loading and delay its release. To incorporate these particles
into chosen substrates (silicon wafer, glass, or polyvinylchloride), the authors coated the particles
with polydopamine and the substrate with a catechol-modified chitosan polymer. This configuration
permitted depositing the negatively charged, heparin loaded MSNs onto chitosan, which was further
bound to the catechol–dopamine coating of substrates. Finally, to prevent undesired detachment,
this dopamine–catechol bond was oxidized with NaIO4 in order to create a non-degradable polymeric
layer. When the authors tested this coating against blood, they found a very low fibrinogen adsorption,
as well as platelet adhesion and hemolysis, which is in concordance with a sustained anticoagulant
release and good biocompatibility. More recently, Wu et al. reported a similar approach but with an
added feature: antibacterial adhesion. To achieving this, the authors loaded the mesopores of MSNs with
two glycan-based structures: agarose for an antibacterial effect and heparin as an anticoagulant [202].
The agarose-heparin loaded MCM-41 nanoparticles were electrostatically immobilized onto the
prepared device, i.e., an amino-modified silicone film. Therefore, the final coating presented a negative
charge and exposed mesopores, which were able to produce effective agarose and heparin release.
The system demonstrated a low hemolytic effect comparable with that of the previous model but with
an additional antibacterial effect against E. coli, gaining additional applicability. However, regarding
the design, the possibility of detaching SBA-15 particles within the bloodstream has to be considered
as a potential risk and must be accounted for in the further development of such devices.
7. Challenges and Future Perspectives
As reviewed, the number of developing therapeutic hybrid nanosystems employing biomolecules
together with mesoporous silica nanoparticles is enormous, as reported over the last few years.
In general, and according to the literature here visited, cancer therapy is by far the most active research
field and the one that exploits the most up-to-date technological advances such as PEGylation, controlled
drug delivery, or the implementation of hybrid nanomaterials, among many others. However, such
technology permitted developing alternative therapies to cancer, applied to other not-so-common
diseases with a promising prognosis. This fact is largely due to the particular structure of MSNs,
with a high capacity to load and release therapeutic molecules within their porous matrix. However,
the advancement of knowledge and the need to adapt these nanomaterials to advanced preclinical
in vivo models, with new aspects in loading and release systems, must be considered when designing
these medical nanosystems. In this context, short therapeutic peptides and small molecules seem to
be the ideal target for transfer to preclinical studies because they can be easily designed, developed,
functionalized, and coupled. Among these new emerging therapeutic strategies with biomolecules
that came to light recently, the most promising for implementation together with mesoporous silica
materials seem to be immune therapy, gene modulation, and anti-infective nano-agents, as can be
determined from the number and quality of related papers. In any case, there are different issues to be
addressed regarding the nanocarriers themselves such as the absence of reliable in vivo pre-clinical
studies, methods of clearance of the nanoplatforms, and how different particles properties (shape, size,
pore symmetry and connectivity, and chemical composition) affect their application in nanomedicine.
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ATP Adenosine triphosphate
Bcl-2 B-cell lymphoma 2
bFGF Basic fibroblast growth factor
BM Biomacromolecule
BMP-2 Bone morphogenetic protein 2
bMSCs Murine bone mesenchymal stem cells
BSA Bovine serum albumin
CA Carbonic anhydrase
cAMP Cyclic adenosine monophosphate
COLL1A1 Collagen type 1
ConA Concanavalin A
CS Chondroitin sulfate
DMOHS Dendritic mesoporous organosilica hollow spheres
DNA Deoxyribonucleic acid
Cyt c Cytochrome c
DOX Doxorubicin
FA Folic acid/folate
gG Immunoglobulin G
GFP Green fluorescent protein
GM-CSF Murine granulocyte-macrophage colony-stimulating factor
GPx Glutathione peroxidase
HMSNs Hollow mesoporous silica nanoparticles
HA Hyaluronic acid
HDFs Human dermal fibroblasts
HOS Human osteosarcoma
HRP Horseradish peroxidase
HSCs Human stem cells
HSP47 Heat-shock protein 47
IDMSN Imidazole dendritic mesoporous silica nanoparticles
IL-2 Interleukin-2
kDa Kilodaltons
LA Lactobionic acid
LDL Low-density lipoprotein
MCM-41 Mobil composition of matter formulation 41
MDR1 Multidrug resistance protein 1
MEF Mouse embryonic fibroblastic cells
MPLA Monophosphoryl lipid A
miRNA Micro ribonucleic acid
mRNA messenger ribonucleic acid
MSNs Mesoporous silica nanoparticles
NA Nucleic acid
NOX4 NADPH oxidase 4
OGP Osteogenic growth peptide
OVA Chicken ovalbumin
PAMAM Polyamidoamine dendrimer
PDA Polydopamine
PEG Polyethylene glycol
PEI Polyethyleneimine
pGFP Fluorescent protein plasmid
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PKM2 Glycolytic enzyme pyruvate kinase
PMDFs Primary mouse dermal fibroblast
ROS Oxygen species
RSNs Rough (non-porous and core–shell) silica nanoparticles
SBA-15 Santa Barbara amorphous formulation 15
rBMSCs Rat bone marrow stromal cells
RCA Rolling circle amplification
shRNA Short hairpin ribonucleic acid
siRNA Small interfering ribonucleic acid
SO Sorafenib
SOD Superoxide dismutase
SPIONs Superparamagnetic iron oxide nanoparticles.
TAT Transactivator of transcription
TnC Tenascin-C
TGFβR-1 Transforming growth factor beta receptor I
VEGF Vascular endothelial growth factor
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